We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Centers for Disease Control and Prevention. Case control study of HIV seroconversion in health care workers after percutaneous exposure to HIV infected blood—France, United Kingdom and United States, January 1988-August 1994. MMWR1995;44:929–933.Google Scholar
2
2.Tokars, JI, Marcus, R, Culver, DH, et al.Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med1993;118:913–919.Google Scholar
3
3.Collier, AC, Coombs, R, Schoenfeld, DA, et al.Treatment for human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med1996;334:1011–1017.CrossRefGoogle ScholarPubMed
4
4.Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR1996;45:468–472.Google Scholar
5
5.Gerberding, J. Prophylaxis for occupational exposure to HIV. Ann Intern Med1996;125:497–501.Google Scholar